Cell-based therapies that employ engineered T cells-including the expression of chimeric antigen receptors (CARs)-to target cancer cells have demonstrated promising responses in clinical trials. However, engineered T cell responses must be regulated to prevent severe side effects such as cytokine storms and off-target responses. Here we present a class of recombinase-based gene circuits that will enable inducible switching between two states of adoptive T cell therapy using an FDA-approved drug, creating a generalizable platform that can be used to control when and how strongly a gene is expressed. These circuits exhibit memory such that induced T cells will maintain any changes made even when the drug inducer is removed. This memory feature avoids prolonged drug inducer exposure, thus reducing the complexity and potential side effect associated with the drug inducer. We have utilized these circuits to control the expression of an anti-Her2-CAR, demonstrating the ability of these circuits to regulate CAR expression and T cell activity. We envision this platform can be extended to regulate other genes in T cell behavior for various adoptive T cell therapies.
Introduction
T cells have emerged as a promising candidate for cell-based therapies, and engineering of T cells to express antigen-specific chimeric antigen receptors (CARs) have enabled programmable targeting of cancer cells [1] [2] [3] [4] . Multiple clinical trials with CARs against B cell cancers have driven up to a 90% complete response rate in patients [5] [6] [7] [8] , and several CAR T cell products targeting acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma have been approved for clinical use in the United States.
Despite these promising clinical results, there are significant safety and efficacy considerations with CAR T cell therapies, often mirroring fundamental regulatory challenges of the immune system 9, 10 . For example, the immune system naturally seeks to prevent autoimmune reactions by selecting against highly autoreactive T cells during their development in the thymus 11 .
However, engineered cancer-specific receptors often target markers that while overexpressed on tumor cells, may still be found at lower levels in healthy tissues 12 . These modified cells have the potential for an autoreactive "on-target, off-tumor" response, which has been observed and proven fatal in at least one clinical trial 13 . In addition, there are numerous regulatory checks that prevent the immune system from responding too strongly against pathogens and causing systemic harm, checks that may become disrupted by engineered T cells. CARs, in particular, can instigate a strong cytokine release in response to antigen stimulation, accelerating the immune response to potentially fatal levels. This cytokine release syndrome (CRS) has been observed in several CAR T cell clinical trials 7, 8 , and a regimen of immunosuppressive drugs is often required to ameliorate the response 5 .
These safety considerations point to the dangerous aspects of what is otherwise the major advantage of cell-based therapies: the ability to drive strong responses based on the cell's own machinery. Targeted cytotoxicity is fundamental to the power of T cell therapies, but it is also the basis of its potential harms. This challenge is compounded by the immense cost-both in time and money-of cell-based therapies, which makes it difficult to iterate this therapy over and over again until it meets a patient's individual needs.
T cell therapies would thus greatly benefit from the development of tools that allow greater control over cell behavior, enabling an already personalized therapy to be customizable towards a patient's immediate and changing needs. Advances in genetic engineering and synthetic biology have provided significant insight into both the design and implementation of such controls in the form of synthetic receptors, protein-based switches, genetic circuits, and genome editing tools 9 . These tools have in turn been used to create "ON-Switch" CARs 14 , combinatorial activation systems 15, 16 , doxycycline-inducible CARs 17 , antibody-inducible CARs 18 , kill switches [19] [20] [21] , pause switches 22 , tunable receptor systems [23] [24] [25] , proliferation switches 26 , and a universal "off the shelf" T cell 27 . These systems all reflect the tremendous potential of synthetic biology approaches in developing safer and more powerful forms of T cell therapy that can be customized to fit each patient.
While these technologies offer important forms of control over T cell behavior, their designs are accompanied by limitations. For example, while kill switches provide vital control in cases where the T cells are toxic to the patient, completely shutting off the therapy may be an extreme response for patients who only require a slight modification of the therapy to abrogate negative reactions. Some approaches are also only limited to certain types of therapy, such as the many CAR receptor designs that strictly provide added flexibility and control to CAR T cell therapy. In addition, certain inducible systems like the "ON Switch" CAR require the drug-inducer to be continuously provided to maintain the ON state, which may be less ideal if permanent changes are required for a patient. Furthermore, prolonged drug-inducer exposure may be detrimental to patients if the inducer has a less than ideal safety profile, even when the drug is FDA-approved.
While these approaches will advance the scope of potential T cell therapies, developing further technologies that are compatible with them may help to expand their use.
To address the need for advanced control of T cell responses for various immunotherapy applications, we have developed a drug-inducible genetic circuit platform that is designed to be lentivirus-compatible, which will facilitate genetic modification of human primary T cells. Our system also has memory capability that reduces the need for prolonged drug administration to maintain gene expression level. We have adapted these circuits to control CAR expression, creating a variety of circuits, including an On Switch (ON), Off Switch (OFF), and Expression
Level Switch (EXP) that controls CAR expression, alters T cell behavior, retains memory, and exhibits activity that can be tuned via drug dosage and duration. These gene switches represent the most versatile switches in T cells and have the potential to improve the safety and efficacy of T cell immunotherapy.
Results

Recombinase-based gene switch for controlling CAR expression
To implement a lentivirus- . We initially developed a Cre/lox-based FLEx switch into Jurkat T cells and observed high toxicity upon Cre induction ( Supplementary Fig. 1 ). We adapted the FLEx switch to operate with the FlpO/frt recombinase system instead, as the Flp recombinase has not been reported to be toxic 33, 34 , using the frt site and its variant f3 site. A similar FlpO-based FLEx switch has been designed using other variant frt sites 35 . To control recombination, we used FlpO conjugated to the mutated estrogen receptor ER T2 36 , which localizes the recombinase to the cytoplasm 29 . Upon induction with the drug 4-hydroxytamoxifen (4-OHT), the recombinase is localized to the nucleus, where it can act upon the FLEx switch (Fig. 1a) . We chose the tamoxifen-inducible Flp for our circuit design because tamoxifen is an FDA-approved drug, which will facilitate implementation into the clinic. We have adapted the FlpOER T2 /frt FLEx switch design to alter the orientation of CAR genes to create a stable ON and stable OFF switch (Fig. 1b) . In addition, we have designed an "Expression Level" (EXP) switch that affects the orientation of the human EF1α promoter relative to the CAR gene, stably taking cells from low expression to high expression of CAR (Fig. 1b) .
Induction of recombinase activity drives changes in CAR expression
We transduced human primary CD4+ T cells with two viruses: one that contained a constitutively expressed FlpOER Fig. 2) , not all induced ON Switch cells express CAR (Fig. 2) . Nor do all uninduced OFF and EXP switch cells express CAR (Fig. 2) . This population heterogeneity is likely due to transduction inefficiency. Indeed, when we integrated these circuits into Jurkat T cells, which generally exhibit greater ease of transduction, we observed cell populations with greater homogeneity (Supplementary Fig. 3 ).
Two key markers of circuit performance are basal switching and switching completeness. Basal switching is best observed in the small population (~8%) of ON Switch that express CAR prior to induction, which indicates a low level basal FlpOER T2 activity (Fig. 2) . This basal level of CAR expression appears to be connected to a higher level of recombinase expression (Supplementary Fig. 2 ). Switching completeness is better observed in the OFF switch, where less than 10% of cells still express CAR at the end of induction. In addition to these markers of circuit activity, we observed high viability and cell growth comparable to wild-type for switchexpressing cells over the course of induction ( Supplementary Fig. 4 ), suggesting that genotoxicity of Flp recombinase is minimal.
Changes in CAR expression impact Jurkat NFAT signaling
The induced changes in CAR expression by our switches are expected to alter T cell responses to antigen stimulation. We quantified the activation of circuit-expressing T cells by stimulating them with plate-bound Her2 antigen and measuring the NFAT transcription reporter level in Jurkat T cells (Fig. 3) . We observed that induced ON switch T cells, which express a CAR after 4-OHT-induction, can be activated with Her2. There was a low level of NFAT reporter expression at higher Her2 doses that suggests some basal CAR expression in uninduced cells, which could be due to a low level of basal recombinase activity. With the OFF switch, we observed that 4-OHT-induced cells have low NFAT reporter activity when stimulated with Her2, corresponding to the loss of CAR expression. The remaining level of NFAT activity in induced cells may be due to incomplete FLEx circuit switching, which could result from factors such as inaccessibility to the integration site. These results are mirrored in ON and OFF switch CD4+ primary T cells that are activated 10 days after induction, where activation is measured via IL-2 production (Fig. 3) .
For EXP switch-expressing Jurkat T cells, we observed that the increase in CAR expression after 4-OHT induction led to a corresponding increase in NFAT-GFP expression (Fig. 3) .
Interestingly, while we observed this effect for a low-affinity Her2-CAR (C6.5G98A, KD = 3.2×10 , the effect on NFAT-GFP activation levels is mitigated at high levels of Her2 antigen, illustrating that the level of T cell activation is dually modulated by the CAR expression level and its antigen-scFv affinity ( Supplementary Fig. 5 ), corroborating similar observations by others 3, 16, 37, 38 . Primary CD4+ T cells expressing the EXP switch also demonstrate an increase in IL-2 production when activated against Her2. Expression of IL-2 in uninduced EXP cells was low and similar to wild-type, which may be due to a combination of the low CAR expression within the cells, the small population of cells expressing CAR overall, and the low affinity of the CAR.
Switch cells exhibit memory when drug is removed
One unique feature of the recombinase-based switch that is not found in other existing gene switches is memory: removal of the drug will maintain any changes made to the cell. Cells that have been switched on will stay on, cells that have been switched off will stay off, and cells that now express greater CAR will continue to express greater CAR. We confirmed this feature for the ON, OFF, and EXP switches in human primary CD4+ T cells. Induced cells that were washed of cells 2 days after induction maintained the same level of CAR expression 15 days post-induction as cells that had been continuously induced for 15 days (Fig. 4) .
Tunability of switching can be driven by drug dosage and duration
While these circuits ostensibly provide a two-state system, the percentage of cells that switched states may be tunable by applying the inducer at different concentrations. Therefore, we treated recombinase-positive primary CD4+ T cells with a range of 4-OHT dosages and showed that the percentage of cell population switched states in the ON and OFF switch can indeed be modulated (Fig. 5a ). In addition, the level of mean CAR expression in the EXP switch can be further tuned via drug dosage.
In cases where the switch takes longer to work, the memory feature enables further tuning of switch dynamics. In particular, varying the duration of drug dosage resulted in varying degrees of switching in Jurkat OFF Switch cells (Fig. 5b, Supplemental Fig. 6 ). However, these results did not extend to primary T cells, where all switches expressed the same level of CAR when induced for only 2 days compared to cells that were induced for much longer (Figure 4) . Jurkat ON and EXP switch cells also did not exhibit drug duration tunability (Supplemental Fig. 6 ).
Discussion
We have presented a recombinase-based genetic circuit system that allows for increased control of primary T cell behavior. The circuits we have presented here are a lentiviral compatible system with memory capability such that continual addition of the drug is not required for maintenance of any desired changes to the cellular state. This capacity for memory would be particularly important for therapeutic strategies that require permanent changes to be made to the cell, such as permanently shutting off expression of a particular gene, enabling only a temporary drug intake to make changes in lieu of asking a patient to continuously consume the drug. These switches can be used to turn a gene ON or OFF, as well as to stably alter the level of gene expression.
The activity of these circuits provides a number of advantages for patients who require a tunable but permanent change made to the behavior of their engineered T cells. While transiently inducible systems, such as a the drug-dimerizable "ON Switch" CAR, can be powerful forms of control, the memory capacity of the circuits described here will enable the development of a broader class of therapeutic strategies that can make long-lasting changes to T cell behavior Optimized use of our recombinase-based switching will rely on careful consideration of the potential application. In particular, there are situations where low levels of basal activity or incomplete switching may carry enough risk that this approach will not be applicable. Careful tuning of recombinase expression or activity may provide further avenues to address these limitations, as could the incorporation of inducible kill switches to selectively kill cells that are not behaving as directed.
T cell therapies will require us to not just rely on the mechanics of the immune system, but to understand the intricacies that are available and necessary for us to fine-tune in order to create a safe and effective treatment. With many developments and tools focused around developing one facet of control, having a platform of genetic circuits that can be applied in different ways creates a wider array of options available to implement T cell therapies.
Methods
Circuit Construction
The circuit we described is comprised of two parts: the inducible recombinase and the FLEx switch. These components were cloned into separate lentiviral backbones using a combination of Gibson and traditional molecular cloning methods. The FlpOER T2 recombinase was cloned into the backbone followed by a T2A ribosomal skip sequence and an mTAG-BFP fluorescent marker.
The FLEx switch was designed using the frt and f3 recombination sites. For the ON and OFF switches, the chimeric antigen receptor sequence was inserted between the recombination sites. The SFFV promoter was used to drive FLEx switch (and thus, CAR) expression. For the expression level switch, the EF1α promoter was inserted between the recombination sites such that the reverse promoter orientation was encoded in the 5' to 3' direction. The CAR was expressed downstream of the FLEx/reverse EF1α promoter.
Primary T cell isolation and transduction
Blood was obtained from the Boston Children's Hospital, and primary CD4+ T cells were 
Jurkat T cell maintenance and transduction
Through transduction and general maintenance, Jurkat T cells were maintained in RPMI media (Lonza) supplemented with 5% fetal bovine serum (Gibco), 2mM glutamine, and 100 U/mL penicillin+100 µg/mL streptomycin. Through analysis, cells were maintained in RPMI media supplemented with 10% fetal bovine serum and 2mM glutamine. . Jurkat cells were exposed to different concentrations of plate-bound Her2 protein, and primary T cells were exposed to 5 ug/mL Her2 An NFAT-GFP transcription reporter and IL-2 were measured for Her2 CAR Jurkat and primary T cell respectively. Cells were plated against Her2 antigen in triplicate, and both NFAT-GFP (arbitrary units, AU) and IL-2 (pg/mL) were plotted as mean and standard deviation. Significance in IL-2 production was determined by unpaired, two-tail T-test (* p<0.05, ** p<0.01) 
